; and (C) ensure access to prescription drugs. (2) Executive agency The Bureau shall be considered an Executive agency, as defined in section 105 of title 5, United States Code. (3) Director (A) Appointment The Bureau shall be headed by a Director (in this Act referred to as the Director ) who shall be appointed by the President, by and with the advice and consent of the Senate. (B) Qualification The President shall nominate the Director from among individuals who are citizens of the United States. (C) Term The Director shall serve for a term of 5 years. The term of the first Director to be appointed shall begin on the date that is 180 days after the date of enactment of this Act. (4) Consultation (A) In general In carrying out the duties under this section, the Bureau shall regularly consult with relevant stakeholders, including patients, representatives of relevant Federal agencies, and medical and health care finance experts. The Bureau shall have regular public meetings to solicit input from relevant stakeholders. (B) Patient engagement (i) In general The Director shall ensure that patients or organizations representing patients have opportunities to meaningfully engage with the Bureau as it conducts its work, including while the Bureau makes appropriate price determinations under section 3(d). Such opportunities may include holding regular panels, forums, and other meetings for patient engagement. (ii) Petition The Director shall establish a process by which patients can petition the entity and raise concerns about the price of their prescription drugs. (C) Consumer Advisory Council (i) Establishment The Director shall establish a Consumer Advisory Council to advise and consult with the Bureau as it conducts its work. (ii) Membership The Council established under this subparagraph shall be composed of not fewer than 6 members appointed by the Director. In appointing members to the Council, the Director shall ensure that at least half of the members of the Council are patients or organizations representing